CN104395458A - 改善对骨骼肌疲劳的抵抗力 - Google Patents

改善对骨骼肌疲劳的抵抗力 Download PDF

Info

Publication number
CN104395458A
CN104395458A CN201380019567.7A CN201380019567A CN104395458A CN 104395458 A CN104395458 A CN 104395458A CN 201380019567 A CN201380019567 A CN 201380019567A CN 104395458 A CN104395458 A CN 104395458A
Authority
CN
China
Prior art keywords
xii
alkyl
skeletal muscle
fatigue
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380019567.7A
Other languages
English (en)
Chinese (zh)
Inventor
F·马利克
J·R·贾斯伯
A·肯尼迪
D·威
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytokinetics Inc
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Priority to CN202010369880.5A priority Critical patent/CN111840294A/zh
Publication of CN104395458A publication Critical patent/CN104395458A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201380019567.7A 2012-04-11 2013-04-11 改善对骨骼肌疲劳的抵抗力 Pending CN104395458A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010369880.5A CN111840294A (zh) 2012-04-11 2013-04-11 改善对骨骼肌疲劳的抵抗力的方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261623003P 2012-04-11 2012-04-11
US61/623,003 2012-04-11
US201261646842P 2012-05-14 2012-05-14
US61/646,842 2012-05-14
US201261693061P 2012-08-24 2012-08-24
US61/693,061 2012-08-24
US201261735809P 2012-12-11 2012-12-11
US61/735,809 2012-12-11
PCT/US2013/036114 WO2013155262A2 (en) 2012-04-11 2013-04-11 Methods for improving resistance to skeletal muscle fatigue

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202010369880.5A Division CN111840294A (zh) 2012-04-11 2013-04-11 改善对骨骼肌疲劳的抵抗力的方法

Publications (1)

Publication Number Publication Date
CN104395458A true CN104395458A (zh) 2015-03-04

Family

ID=49328282

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380019567.7A Pending CN104395458A (zh) 2012-04-11 2013-04-11 改善对骨骼肌疲劳的抵抗力
CN202010369880.5A Pending CN111840294A (zh) 2012-04-11 2013-04-11 改善对骨骼肌疲劳的抵抗力的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202010369880.5A Pending CN111840294A (zh) 2012-04-11 2013-04-11 改善对骨骼肌疲劳的抵抗力的方法

Country Status (15)

Country Link
US (2) US20150250784A1 (https=)
EP (1) EP2836590A4 (https=)
JP (2) JP6352244B2 (https=)
KR (1) KR102163931B1 (https=)
CN (2) CN104395458A (https=)
AU (3) AU2013245917A1 (https=)
BR (1) BR112014025251B1 (https=)
CA (1) CA2869675C (https=)
EA (1) EA032480B1 (https=)
HK (1) HK1206389A1 (https=)
IL (2) IL234886A (https=)
MX (1) MX2014012179A (https=)
PH (1) PH12014502286B1 (https=)
SG (2) SG11201406359TA (https=)
WO (1) WO2013155262A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
BR112014000742A2 (pt) 2011-07-13 2016-08-23 Andrew A Wolff terapia de combinação de als
JP6387360B2 (ja) 2013-03-14 2018-09-05 ノバルティス アーゲー 変異ｉｄｈの阻害薬としての３−ピリミジン−４−イル−オキサゾリジン−２−オン
SI3137622T1 (sl) * 2014-04-29 2022-05-31 Cytokinetics, Inc. Postopki za zmanjšanje upada vitalne kapacitete
KR102431436B1 (ko) 2014-08-29 2022-08-10 테스 파마 에스.알.엘. α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제
JP6573618B2 (ja) * 2014-09-09 2019-09-11 アステラス製薬株式会社 尿失禁予防用及び／又は治療用新規医薬組成物
SG11201806416XA (en) 2016-02-12 2018-08-30 Astellas Pharma Inc Tetrahydroisoquinoline derivatives
WO2018011681A1 (en) 2016-07-14 2018-01-18 Pfizer Inc. Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
IL289237B2 (en) 2019-07-23 2026-03-01 Amorphical Ltd Amorphous calcium carbonate for improving athletic performance
AU2020321955A1 (en) 2019-07-30 2022-03-17 Eikonizo Therapapeutics, Inc. HDAC6 inhibitors and uses thereof
US11981644B2 (en) 2020-11-06 2024-05-14 Cytokinetics, Inc. Bicyclic 1,4-diazepanones and therapeutic uses thereof
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
TW202345813A (zh) 2022-04-08 2023-12-01 美商艾科尼佐療法股份有限公司 㗁二唑ｈｄａｃ６抑制劑及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090029345A1 (en) * 2006-08-01 2009-01-29 Alan Russell Modulating skeletal muscle
CN101522681A (zh) * 2006-08-02 2009-09-02 赛特凯恩蒂克公司 特定的化学个体、组合物和方法
US20110014212A1 (en) * 2006-08-02 2011-01-20 Aaron Hinken Certain Chemical Entities, Compositions and Methods
WO2011133888A1 (en) * 2010-04-23 2011-10-27 Cytokinetics, Inc. Certain amino-pyrimidines, compositions thereof, and methods for their use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005139081A (ja) * 2003-11-04 2005-06-02 Takada Seiyaku Kk ビントペロール含有製剤
EP2244711A4 (en) * 2008-02-04 2011-08-24 Cytokinetics Inc CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
KR20160046693A (ko) * 2012-04-02 2016-04-29 싸이토키네틱스, 인코포레이티드 횡격막 기능을 향상시키는 방법들

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090029345A1 (en) * 2006-08-01 2009-01-29 Alan Russell Modulating skeletal muscle
CN101522681A (zh) * 2006-08-02 2009-09-02 赛特凯恩蒂克公司 特定的化学个体、组合物和方法
US20110014212A1 (en) * 2006-08-02 2011-01-20 Aaron Hinken Certain Chemical Entities, Compositions and Methods
WO2011133888A1 (en) * 2010-04-23 2011-10-27 Cytokinetics, Inc. Certain amino-pyrimidines, compositions thereof, and methods for their use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AY LIN KHO等: "The sarcomeric cytoskeleton as a target for pharmacological intervention", 《CURRENT OPINION IN PHARMACOLOGY》 *
HIATT等: "Efficacy and tolerability of the novel fast skeletal muscle troponin activator, CK-2017357, in patients with claudication", 《22ND ANNUAL SESSIONS OF THE SOCIETY FOR VASCULAR MEDICINE》, 31 December 2011 (2011-12-31) *
李渝萍等: "快速骨骼肌型肌钙蛋白Ⅰ的研究进展", 《生命的化学》, vol. 24, no. 3, 31 December 2004 (2004-12-31) *

Also Published As

Publication number Publication date
AU2019268177A1 (en) 2019-12-12
JP2018048209A (ja) 2018-03-29
PH12014502286A1 (en) 2014-12-15
HK1206389A1 (en) 2016-01-08
CN111840294A (zh) 2020-10-30
IL250473A0 (en) 2017-03-30
US20150250784A1 (en) 2015-09-10
KR102163931B1 (ko) 2020-10-12
SG10201704166RA (en) 2017-06-29
EA032480B1 (ru) 2019-06-28
EP2836590A2 (en) 2015-02-18
IL234886A (en) 2017-02-28
PH12014502286B1 (en) 2014-12-15
EP2836590A4 (en) 2016-04-13
EA201491666A1 (ru) 2015-03-31
AU2018200930A1 (en) 2018-03-01
KR20160046694A (ko) 2016-04-29
AU2013245917A1 (en) 2014-10-23
WO2013155262A3 (en) 2013-12-27
MX2014012179A (es) 2015-07-14
JP6535727B2 (ja) 2019-06-26
JP6352244B2 (ja) 2018-07-04
BR112014025251B1 (pt) 2021-03-02
WO2013155262A2 (en) 2013-10-17
US20190167676A1 (en) 2019-06-06
JP2015516392A (ja) 2015-06-11
CA2869675A1 (en) 2013-10-17
CA2869675C (en) 2022-06-14
SG11201406359TA (en) 2014-11-27

Similar Documents

Publication Publication Date Title
JP6535727B2 (ja) 骨格筋疲労に対する耐性を向上させるための方法
AU2017272286B2 (en) Methods for improving diaphragm function
TWI473803B (zh) 作為阿伐７正向異位調節劑之嗎福啉基噻唑
JP7514534B2 (ja) 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法
JP2022506687A (ja) ピリダジノン化合物およびその使用
Patil et al. Pyridine and its biological activity: a review
AU2007333129A1 (en) Pharmaceutical compositions and their methods of use
KR20130129906A (ko) 시그마 수용체-매개 장애를 치료하기 위한 시클릭 아미드 유도체의 사용 방법
KR20200090198A (ko) 트로포미오신 수용체 키나제 A(TrkA) 저해제로서의 피리미딘 유도체
HK1261324A1 (en) Methods for improving diaphragm function
WO2025189066A1 (en) Modulators of g protein-coupled receptor 55 (gpr55)
EA050889B1 (ru) Соединения пиридазинонов и их применения
EA041725B1 (ru) Применение активатора тропонина скелетных мышц
Elkhouly Synthesis of condensed 1, 4-dihydropyridine derivatives and evaluation of their calcium channel modulating and antioxidant activities

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20160720

Address after: American California

Applicant after: Cytokinetics Inc.

Address before: American California

Applicant before: Cytokinetics Inc.

Applicant before: F * Malik

Applicant before: JASPER JEFFREY R

Applicant before: Kennedy Adam

Applicant before: D *wei

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150304